Digital Therapeutics Market - The Health Benefits and Business Potential

Digital-native start-ups and healthcare incumbents can both play important roles in building and scaling digital therapeutics to improve the management of chronic health conditions.

The global digital therapeutics market size is expected to surpass around USD 25.32 billion by 2032 from valued at USD 3.91 billion in 2022 and growing at a CAGR of 20.54% from 2023 to 2032.

Globally, the prevalence of chronic diseases is on the rise, posing a growing burden on healthcare systems. Regrettably, a significant number of these ailments are irreversible, requiring ongoing medication for effective management. Nevertheless, numerous patients encounter challenges in adhering to prescribed medications and adopting the necessary behavioral and lifestyle adjustments to effectively handle their conditions and stabilize their health. Frequently, healthcare professionals, including physicians, face limitations in monitoring the adherence of patients to recommended treatments and lifestyle changes. Consequently, the overall disease burden on a population scale surpasses optimal levels.

Ask here for sample copy@ https://www.visionresearchreports.com/report/sample/37632

The existing challenges have spurred a demand for comprehensive solutions in disease management, and digital technologies emerge as the most effective enablers. In 2021, global funding for digital health experienced a substantial 79% growth compared to the previous year, reaching a total of $57.2 billion. Notably, significant attention and financial support have been directed towards digital therapeutics, encompassing various intervention points throughout the patient journey. These interventions include monitoring, medication adherence, behavioral engagement, personalized coaching, and real-time customized health recommendations. Specifically within the realm of digital health, funding for digital therapeutics, which extends to mental health solutions, has surged even more rapidly, witnessing a remarkable 134% increase from the preceding year and reaching a total of $8.9 billion in 2021.

The potential impact here is substantial, encompassing both notable improvements in clinical outcomes and economic advantages for stakeholders and societies. For instance, research indicates that the implementation of digital disease management can result in a significant 45% decrease in the three-month rate of major adverse cardiovascular events (MACEs) and a noteworthy 50% reduction in the 30-day readmission rates for patients recovering from acute myocardial infarction (AMI). Additionally, it has been shown to contribute to a one percentage point reduction in hemoglobin A1c (HbA1c) levels among patients with type 2 diabetes. These findings highlight the considerable influence of digital disease management in not only saving lives but also promoting overall patient health, consequently reducing costs for various stakeholders, including the patients themselves.

Research has shown that digital disease management can drive a 45 percent reduction in the three-month rate of major adverse cardiovascular events (MACEs) and a 50 percent reduction in the 30-day readmission rates for patients.

Many players are trying to disrupt the disease management space and develop new innovative models to manage chronic diseases. New-age start-ups bring radical, unconstrained perspectives, while incumbents contribute a much more detailed understanding of the challenges and various stakeholders. Ultimately, both start-ups and incumbents have critical roles to play in disrupting the space and scaling up solutions.

Access the Full Report Study@ https://www.visionresearchreports.com/report/checkout/37632

Digital therapeutics can play an important role in chronic-disease management

The prevalence of chronic diseases is on a continual rise worldwide and is projected to persist in its upward trend. Chronic conditions, including cardiovascular disease, cancer, diabetes, and respiratory disease, played a role in 75 percent of global deaths in 2010 and increased to 79 percent by 2020. Projections from experts indicate that by 2030, chronic diseases are anticipated to contribute to as much as 84 percent of the total global mortality.

Ineffectual monitoring and adherence to prescribed medications pose significant challenges to the management of chronic diseases. A 2021 global study reveals that patient compliance with type 2 diabetes medications ranges from 69 to 79 percent.

Managing chronic diseases requires not only medication but also regular monitoring and lifestyle adjustments. Consequently, there is a pressing need for enhanced end-to-end solutions that actively and comprehensively monitor patient health, promoting behavioral changes to enhance adherence to prescribed medications, dietary plans, and lifestyles.

Digital technologies emerge as crucial facilitators in addressing these challenges and improving disease management. The substantial impact potential of digital therapeutics is underscored by the fact that nearly two-thirds of the global population now has internet access.

Research has shown that digital solutions for disease management can drive better outcomes for patients living with chronic diseases.

Examples include the following:

• A Poland National Health Fund study involving ten thousand patients demonstrated a 45% decrease in the three-month Major Adverse Cardiovascular Events (MACE) rate and a 40% reduction in 12-month mortality rates through managed care following Acute Myocardial Infarction (AMI). The study incorporated cardiac rehabilitation with physician supervision, counseling sessions focusing on lifestyle modifications, education regarding associated risk factors, therapy, and in-person relaxation sessions.

• A collaborative study between the Mayo Clinic and Healarium revealed a 40% decrease in three-month rehospitalizations and emergency department visits for patients recovering from Acute Myocardial Infarction (AMI). Additionally, participants experienced a weight reduction of 4.0 kilograms and a 10.8-millimeter decrease in systolic blood pressure. The study implemented the monitoring of vital signs, diet, and physical activity, along with features such as setting reminders and goals, providing information on current health status, and offering educational courses for patients.

• A study conducted by Johns Hopkins and Corrie Health in the United States, involving over one thousand patients, demonstrated a 50% decrease in the 30-day readmission rate among individuals recovering from Acute Myocardial Infarction (AMI) through the implementation of digital-health-based interventions. The study incorporated continuous monitoring of vital signs using connected devices, educational content covering procedures, risk factors, and lifestyle modifications, medication management through reminders and adherence tracking, communication with the care team, mood tracking, and the ability to check medication side effects.

• Participants in Virta Health’s ten-week nonrandomized parallel arm study, consisting of 262 outpatients with type 2 diabetes, demonstrated a one percentage-point reduction in HbA1c levels. This reduction was observed in patients engaged in an online patient community, where they received personalized nutritional recommendations from dedicated health coaches, utilized continuous glucose monitoring kits, and engaged in online counseling with doctors.

Eight key elements of impactful digital therapeutics solutions

Strong digital therapeutics solutions typically contain most or all of the following eight elements:

• Consistent monitoring, measurement, and feedback are facilitated through the use of connected medical devices. Devices such as smart inhalers designed for respiratory conditions or continuous glucose monitors used in diabetes management offer patients nudges and alerts when readings fall outside the normal range. For instance, Biofourmis, based in Boston, utilizes digital therapeutics by implementing continuous monitoring through connected medical devices. The company provides a FDA-approved digital platform, prescribed by doctors, for individuals with chronic heart conditions. Their specialized wearable devices deliver comprehensive chronic heart care management, incorporating automated medication oversight alongside a remote clinical care team with expertise in various disciplines. As of 2022, the company is valued at $1.3 billion.

• Ensuring communication between payers and providers is essential. When patients provide access to their vital statistics, insurance companies, caregivers, and employers can incentivize them for progress in managing or enhancing their chronic health conditions. For instance, the Livongo program, part of Teladoc Health, enables individuals with diabetes to regularly monitor their condition. It sends alerts via Bluetooth to an app on their phones and their caregivers’ phones if readings surpass normal ranges. Over time, Livongo participants have experienced positive outcomes, including a 0.8 percentage-point reduction in HbA1c for diabetics, a 10.0-millimeter decrease in blood pressure for patients with hypertension, a 1.8-point reduction in body mass index, and a 7.0 percent weight loss. Livongo allows payers and providers to recognize and reward positive behavior while discouraging or penalizing poor adherence to health plans prescribed by providers.

• Individualized guidance and assistance are available for patients seeking personalized coaching. They can engage with dedicated coaches to receive a customized diet and exercise regimen designed to address their specific chronic illnesses. This approach proves highly effective from a therapeutic standpoint. A meta-analysis of digital health interventions focused on blood pressure management demonstrated that incorporating digital counseling alongside antihypertensive medical therapy led to a 50 percent reduction in systolic blood pressure compared to control groups. An illustration of this is Hinge Health, which has established a $6.2 billion business. The company provides wearable sensors in conjunction with personalized exercise therapy and one-on-one health coaching.

• Behavioral modification through gamification is a feature of digital therapeutics solutions. These solutions incorporate gamified challenges and incentives to monitor and enhance adherence to prescribed diets, lifestyle practices, and medications. An illustration of this is Discovery, a South African health insurance company, which motivates its members to adopt healthier choices. The Vitality behavioral change program offered by Discovery combines data analytics with rewards and incentives, encouraging members to make healthier lifestyle choices.

• Establishing a vibrant community is essential. A dynamic virtual patient community can enhance adherence by inspiring and challenging patients to meet their personal health goals. As an example, a study involving seven thousand patients with conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Parkinson’s disease, HIV, fibromyalgia, or mood disorders revealed that nearly 60 percent believed that the PatientsLikeMe health network contributed to a better understanding of medication side effects. Additionally, the study found that almost a quarter of patients with mood disorders required less inpatient care, attributing it to their engagement with the PatientsLikeMe site.

• Health Marketplace. According to a recent survey, 90% of healthcare leaders are of the opinion that patients engaging with digital health ecosystems prefer a seamless, integrated experience rather than fragmented point solutions. Healthcare companies can address this demand for integration by providing digital health marketplaces that enable users to access prescribed medications, health supplements, wellness products, and diagnostic tests with a simple click of a button.

• Educating Patients. Digital educational resources offer patients and their families valuable information about medical conditions, available treatments, dietary considerations, and choices for maintaining a healthy lifestyle. As an example, the Midday app, a collaborative effort between Mayo Clinic and digital health start-up Lisa Health, offers support, including informative content, to women going through menopause.

• Utilizing Advanced Analytics for Health Event Prediction and Prevention. Current efforts are underway to develop data algorithms aimed at recognizing and predicting factors that could lead to healthcare events. These algorithms have the potential to recommend proactive measures, indicating when to take preventative action or suggesting lifestyle and behavioral changes that could help avert adverse events.

How incumbents can thrive in the digital therapeutics space

Digital therapeutics hold significant potential for alleviating disease burdens, enhancing clinical outcomes, aiding providers in making more informed treatment decisions, and improving the lives of patients by offering more effective ways to manage chronic health conditions. Additionally, digital therapeutics provide established entities with access to new segments of the healthcare value chain, providing an opportunity to participate in the broader end-to-end healthcare market. Given these prospects, healthcare and pharmaceutical incumbents may want to explore strategies to compete and succeed in this evolving space.

Incumbents possess inherent advantages in developing digital therapeutics offerings. They already have direct access to patients and a profound understanding of the challenges in the disease management journey. Furthermore, they possess a comprehensive understanding of the scientific aspects of diseases that need integration into digital health solutions.

Nevertheless, incumbents must undertake certain initiatives to remain competitive in the realm of digital therapeutics. Successfully launching and scaling such offerings may necessitate the recruitment or upskilling of employees with expertise in product development, design, technology, medicine, data science, and strategic partnerships. Incumbents should anticipate a three to five-year investment period to build their digital capabilities and instill a culture, vision, mission, and values in their new digital workforce to effectively compete against agile startups.

Incumbents that act swiftly still have an opportunity to secure a first-mover advantage in the burgeoning digital therapeutics sector, where promising startups can achieve multibillion-dollar valuations. By developing their own digital therapeutics offerings, incumbents may also fortify their positions, safeguarding their core businesses from potential disruptions by external forces.

Key Players

• Omada Health, Inc.
• WellDoc, Inc.
• 2Morrow, Inc.
• Livongo Health
• Propeller Health
• Pear Therapeutics
• Twine Health, Inc.
• Canary Health, Inc.
• Noom Health, Inc.
• Mango Health, Inc.

Market Segmentation

• By Application
  • Diabetes
  • Obesity
  • CVD
  • CNS Disease
  • Respiratory Diseases
  • Smoking Cessation
  • Others

• By End-use
  • Patients
  • Providers
  • Payers
  • Employers
  • Others

Access the Full Report Study@ https://www.visionresearchreports.com/report/checkout/37632

USA - +1 650 460 3308 | IND - +91 93077 85324 OR sales@visionresearchreports.com